Form 4 for RCKT ROCKET PHARMACEUTICALS, INC.
Accepted 2024-02-21 00:00:00 ET · period of report 2024-02-16 · accession 0001140361-24-008887 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-02-21 | 2024-02-16 | RCKT | White Mark Andrew | Chief Medical Off | A - Grant | $0.00 | +11.1K | 87.8K | +14% | $0 |
| D | 2024-02-21 | 2024-02-16 | RCKT | White Mark Andrew | Chief Medical Off | A - Grant | $0.00 | +32.7K | 32.7K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-16 | A | A | 11,096 | $0.00 | 87,758 | D | — | — | (F1) Holdings are Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. One-third (1/3) of such RSUs will become fully vested on February 16, 2025, with the remaining shares vesting in equal quarterly installments over the following two years. |
| 2 | Derivative | Stock Option (Right to Buy) | 2024-02-16 | A | A | 32,727 | $0.00 | 32,727 | D | $30.01 · — to 2034-02-16 | 32,727 Common Stock | (F2) This option represents a right to purchase a total of 32,727 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on February 16, 2025, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. |